Overview
TLSI market data
Price History
TLSI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.20 – $7.95 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $269 · P/B 5.02 · P/S 5.99.
Company News
Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8Benzinga · May 13, 2026, 8:17 PM
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 ResultsBenzinga · May 13, 2026, 5:42 PM
Dow Falls 200 Points; US Producer Prices Surge In AprilBenzinga · May 13, 2026, 1:49 PM
TriSalus Life Sciences shares are trading lower after the company reported mixed Q1 financial results and cut its FY26 sales guidance below estimates.Benzinga · May 13, 2026, 1:25 PM
TriSalus Life Sciences Q1 2026 Earnings Call: Complete TranscriptBenzinga · May 12, 2026, 9:35 PM
TriSalus Life Sciences Lowers FY2026 Sales Guidance from $60.000M-$62.000M to $54.000M-$57.000M vs $59.960M EstBenzinga · May 12, 2026, 8:05 PM
TriSalus Life Sciences Q1 EPS $0.03 Beats $(0.16) Estimate, Sales $8.899M Miss $10.440M EstimateBenzinga · May 12, 2026, 8:05 PM